Retrovir
Primær information
- Handelsnavn:
- Retrovir 10 mg/ml oral opløsning
- Aktiv bestanddel:
- ZIDOVUDIN
- Tilgængelig fra:
- ViiV Healthcare UK Limited
- ATC-kode:
- J05AF01
- INN (International Name):
- zidovudine
- Dosering:
- 10 mg/ml
- Lægemiddelform:
- oral opløsning
- Brugt til:
- Mennesker
- Medicin typen:
- Allopatiske stof
Dokumenter
- for den brede offentlighed:
- Indlægsseddel
-
- for sundhedspersonale:
- Produktresumé
-
Lokation
- Fås i:
-
Danmark
- Sprog:
- dansk
Andre oplysninger
Status
- Kilde:
- Lægemiddelstyrelsen - Danish Medicines Agency
- Autorisation status:
- Markedsført
- Autorisationsnummer:
- 14194
- Sidste ændring:
- 17-07-2018
Indlægsseddel
- Adgang til dette dokument er kun tilgængelig for registrerede brugere.
Tilmeld dig nu for fuld adgang
10-9-2018
Orphan designation: Autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3-zeta chimeric antigen receptor (axicabtagene ciloleucel), for the: Treatment of primary mediastinal large B-cell lymphoma
Europe - EMA - European Medicines Agency
10-9-2018
Orphan designation: Autologous T cells transduced with retroviral vector encoding an anti-CD19 CD28/CD3 zeta chimeric antigen receptor (axicabtagene ciloleucel), for the: Treatment of diffuse large B cell lymphoma
Europe - EMA - European Medicines Agency
5-9-2018
Human medicines European public assessment report (EPAR): Strimvelis, autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence, Revision: 2, Authorised
Europe - EMA - European Medicines Agency
31-8-2018
Human medicines European public assessment report (EPAR): Zalmoxis, allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (ΔLNGFR) and the herpes simple
Europe - EMA - European Medicines Agency
12-6-2018
Human medicines European public assessment report (EPAR): Lamivudine/Zidovudine Teva, lamivudine / zidovudine, Revision: 9, Authorised
Europe - EMA - European Medicines Agency
27-8-2018
Strimvelis (Orchard Therapeutics (Netherlands) B.V.)
Strimvelis (Active substance: autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)5703 of Mon, 27 Aug 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/3854/T/14
Europe -DG Health and Food Safety
1-8-2018
Strimvelis (GlaxoSmithKline Trading Services Limited)
Strimvelis (Active substance: autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence) - Centralised - Yearly update - Commission Decision (2018)5217 of Wed, 01 Aug 2018
Europe -DG Health and Food Safety
30-7-2018
Zalmoxis (MolMed S.p.A.)
Zalmoxis (Active substance: Allogeneic T cells genetically modified with a retroviral vector encoding for a truncated form of the human low affinity nerve growth factor receptor (?LNGFR) and the herpes simplex I virus thymidine kinase (HSV-TK Mut2)) - Centralised - Renewal - Commission Decision (2018)5118 of Mon, 30 Jul 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/2801/R/10
Europe -DG Health and Food Safety